0%
Print report
Variant interpretation report

TET2 c.5192del, p.Gly1731AlafsTer14

NM_001127208.3:c.5192del NP_001120680.1:p.(Gly1731AlafsTer14) Frameshift · exon 11 View identifiers
Classification
Uncertain significance

Variant description:

The TET2 NM_001127208.3:c.5192del (NP_001120680.1:p.(Gly1731AlafsTer14)) frameshift variant has previously been reported in somatic cancers (COSMIC; COSV54406307, n = 1 time). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About TET2

TET2 encodes an enzyme that converts 5-methylcytosine to 5-hydroxymethylcytosine, a key step in active DNA demethylation that helps regulate gene expression. It is important for normal blood cell formation, and defects in the gene are associated with several myeloproliferative disorders. TET2 acts as a tumor suppressor, and its mutations are most often found in blood cancers, where loss of its function can cooperate with other mutations to promote malignancy. Mutations are also found in people with clonal hematopoiesis who have no apparent blood disease but carry an increased risk of developing hematologic cancer with aging.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 2 Benign evidence criteria: 0
Pathogenic criteria applied · 2
PVS1Strong
PVS1 · strong

Strong: The frameshift in exon 11 of 11 is predicted to escape NMD, so PVS1 is downgraded from very strong under the NMD-escape rule.

PM2Supporting
PM2 · supporting

Met at supporting strength: the variant is absent from gnomAD v2.1 and v4.1, satisfying the supplied PM2 frequency threshold of <=0.0001.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PVS1 (strong) plus PM2 (supporting) does not meet a generic ACMG/AMP Likely Pathogenic or Pathogenic combination threshold.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

SpliceAI score
0.011 maximum delta

Recorded SpliceAI maximum delta score: 0.011. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
1 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV54406307, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 5 not met · 11 not assessed · 10 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

PS4 and PP4 remain not assessed because variant-specific case-control data and patient phenotype/family history were not supplied.

PP5 and BP6 are not met because the exact variant is absent from ClinVar and has no expert-panel pathogenic or benign classification.

BP5 is not met because a single somatic COSMIC observation does not establish an alternate molecular basis in a clinical disease case.

Met · 2

PVS1 StrongACMG_2015Strong: The frameshift in exon 11 of 11 is predicted to escape NMD, so PVS1 is downgraded from very strong under the NMD-escape rule. Details ▾Hide ▴
Reasoning

NM_001127208.3:c.5192del is a frameshift variant in TET2 transcript variant 1, producing NP_001120680.1:p.(Gly1731AlafsTer14), with a premature termination codon in exon 11 of 11. TET2 loss of function is supported as a germline disease mechanism in the available gene-level context. The affected transcript is MANE Select/refseq Select, and the variant is exonic in exon 11. Because the premature termination occurs in the terminal exon, the transcript is predicted to escape the canonical exon-junction-complex NMD mechanism; this is the named downgrade from the default very strong PVS1 strength to strong. The truncation removes the C-terminal portion of the 2,003-residue protein, ending the predicted product at residue 1,744, and is not an in-frame repeat-region change. No evidence indicates that the affected exon is irrelevant or enriched for population loss-of-function variation. Therefore PVS1 is met at strong strength rather than very strong.

Rule
PVS1: Null variant (nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.
Evidence considered
  • NM_001127208.3:c.5192del is annotated as a frameshift producing NP_001120680.1:p.(Gly1731AlafsTer14).
  • The variant is in exon 11 of 11 on the MANE Select/refseq Select transcript NM_001127208.3, supporting transcript relevance.
  • TET2 loss of function is supported as a germline disease mechanism in the gene-level PVS1 eligibility assessment.
  • The premature termination is in the terminal exon, so canonical exon-junction-complex-mediated NMD is expected to be escaped; this specifically downgrades the default PVS1 very strong strength to strong.
  • The predicted product terminates at residue 1744 versus the 2003-residue reference protein, a truncation of 259 residues, and the variant is not an in-frame repeat-region indel.
Sources
pvs1_gene_contextpvs1_variant_assessmentpvs1_generic_framework ↗
PM2 SupportingACMG_2015Met at supporting strength: the variant is absent from gnomAD v2.1 and v4.1, satisfying the supplied PM2 frequency threshold of <=0.0001. Details ▾Hide ▴
Reasoning

PM2 is met at supporting strength. NM_001127208.3:c.5192del is reported absent from gnomAD v2.1 and gnomAD v4.1, and the available non-cancer subsets also report it absent. No alternate population allele count or frequency is provided. This satisfies the generic absent-from-controls concept and is assigned supporting strength using the supplied ClinGen SVI threshold of <=0.0001; no VCEP-specific population source or threshold governs this case.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 reports NM_001127208.3:c.5192del absent.
  • gnomAD v4.1 reports NM_001127208.3:c.5192del absent.
  • The available gnomAD v2.1 non-cancer and v3.1 non-cancer records also report the variant absent; no governing VCEP requires one of these subsets in this generic-rules case.
  • The supplied generic ClinGen SVI calibration assigns PM2 supporting strength at <=0.0001 (identified in the governing prompt with ClinGen SVI 2020 and PMID:25741868).
Sources

Not met · 5 · evaluated, threshold not reached

PP5 ACMG_2015Not met: ClinVar has no exact-variant record or expert-panel Pathogenic/Likely pathogenic classification to support PP5. Details ▾Hide ▴
Reasoning

The exact variant is absent from ClinVar, with no expert-panel Pathogenic or Likely pathogenic classification. Therefore, the requirement for a reputable source to report this variant as pathogenic is not met, and ordinary or aggregate submissions cannot be used to trigger PP5.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant search for TET2 NM_001127208.3:c.5192del returned no result; consequently, no expert-panel pathogenic classification was available.
Sources
BA1 ACMG_2015Not met: gnomAD v2.1 and v4.1 report the variant absent, with no grpmax FAF reaching the BA1 threshold of 0.05. Details ▾Hide ▴
Reasoning

BA1 is not met. The TET2 NM_001127208.3:c.5192del variant is absent from gnomAD v2.1 and gnomAD v4.1, with no reported allele frequency or grpmax FAF; therefore there is no population frequency at or above the generic stand-alone threshold of 0.05. The variant is an indel, so the ACMG/AMP caveat that indels may be poorly called by next-generation sequencing remains relevant, but the available gnomAD records do not provide positive frequency evidence. The absence of a frequency also avoids the separate concern that a high-frequency reduced-penetrance allele could conflict with a pathogenic interpretation.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 reports NM_001127208.3:c.5192del absent; no allele frequency or grpmax FAF is reported.
  • gnomAD v4.1 reports NM_001127208.3:c.5192del absent; no allele frequency or grpmax FAF is reported.
  • The generic BA1 calibration supplied for this interpretation is >=0.05, identified as the ACMG/AMP 2015 stand-alone benign allele-frequency threshold (PMID:25741868).
  • The governing ACMG/AMP caveat notes that population data for indels may be poorly called by next-generation sequencing.
Sources
BS1 ACMG_2015Not met: gnomAD v2.1 and v4.1 report no observed alleles, so no grpmax FAF exceeds the generic BS1 threshold of 0.01. Details ▾Hide ▴
Reasoning

BS1 is not met on population frequency. The variant is absent from gnomAD v2.1 and gnomAD v4.1, so no filtering allele frequency or grpmax FAF is available that exceeds the generic default threshold of 0.01. Because there is no elevated frequency to interpret, ancestry-specific founder effects and a maximum-credible-allele-frequency calculation are not triggered for this criterion; no prevalence, penetrance, or allelic-heterogeneity inputs are available in the case for a gene-specific threshold.

Rule
Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v2.1 reports the variant absent, with no filtering allele frequency or grpmax FAF.
  • gnomAD v4.1 reports the variant absent, with no filtering allele frequency or grpmax FAF.
  • The generic BS1 default supplied for this interpretation is >=0.01; per-gene maximum-credible-frequency derivation is preferred under Whiffin et al. 2017 (PMID:28518168), but no elevated frequency requiring that analysis is present.
Sources
BP5 ACMG_2015Not met: COSMIC reports one somatic occurrence, but no case with an established alternate molecular basis for the disease was documented. Details ▾Hide ▴
Reasoning

COSMIC reports the variant once as a somatic cancer alteration, but this is not documentation that the variant was found in a case with an alternate molecular basis for the disease under evaluation. No clinical case with an established alternate molecular cause was supplied; the criterion is therefore not met.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • COSMIC records COSV54406307 for TET2 c.5192del with somatic count n = 1; the record does not establish an alternate molecular basis in a clinical case for the disease being assessed.
Sources
BP6 ACMG_2015Not met: ClinVar has no exact-variant record or expert-panel Benign/Likely benign classification to support BP6. Details ▾Hide ▴
Reasoning

The exact variant is absent from ClinVar, with no expert-panel Benign or Likely benign classification. Therefore, no qualifying reputable benign report is available for BP6; ordinary laboratory submissions, aggregate labels, and non-expert assertions would not qualify.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar exact-variant search for TET2 NM_001127208.3:c.5192del returned no result; consequently, no expert-panel benign classification was available.
Sources

Not assessed · 11 · no assessment recorded

PS2 ACMG_2015Not assessed: confirmed maternity, paternity, proband disease status, and absence of family history are not documented. Details ▾Hide ▴
Reasoning

PS2 cannot be assessed because there is no documented evidence establishing that the variant is de novo, no confirmed maternity and paternity, no documented disease phenotype for the proband, and no family-history assessment. The available evidence does not report parental testing or meiosis-level segregation data.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • No case evidence documents parental testing, confirmed maternity and paternity, de novo status, proband disease status, or absence of family history.
Still missing
  • Documented proband phenotype and diagnosis
  • Confirmed maternity and paternity
  • Parental variant testing
  • Family-history assessment
PS3 ACMG_2015Not assessed: no validated assay directly tested c.5192del, and the available study assayed different TET2 mutants rather than this variant. Details ▾Hide ▴
Reasoning

No validated, reproducible functional assay directly tested NM_001127208.3:c.5192del or p.(Gly1731AlafsTer14). PMID:21057493 provides gene-level context: several different TET2 mutants showed reduced 5-hydroxymethylcytosine in HEK293T assays, but the case variant was not mentioned and was not assayed. This does not establish variant-specific support for a damaging effect under PS3.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:21057493, Results: HEK293T cells expressing seven of nine tested TET2 mutant proteins had significantly less genomic 5-hydroxymethylcytosine than cells expressing wild-type TET2; the tested substitutions were H1802Q/R, R1817S/M, W1211R, P1287S, and C1834D.
  • PMID:21057493, the paper-extracted search for TET2 c.5192del and p.(Gly1731Afs*14) found no mention of this variant; therefore its gene-level functional findings cannot be assigned as variant-specific PS3 evidence.
Still missing
  • A validated, reproducible in vitro or in vivo assay directly testing TET2 c.5192del/p.(Gly1731AlafsTer14) is unavailable.
  • Variant-specific assay controls and quantitative functional results are unavailable.
Sources
PS4 ACMG_2015Not assessed: no variant-specific affected-case/control counts, odds ratio, or 95% confidence interval were available to test the PS4 threshold OR > 5.0 with CI excluding 1.0. Details ▾Hide ▴
Reasoning

No case-control comparison for NM_001127208.3:c.5192del was identified in the supplied literature. The reviewed paper PMID:21057493 does not mention this variant and reports gene-level functional findings only; therefore, there are no affected-case and control counts or matched-ancestry control frequency from which to compute an odds ratio and 95% confidence interval. The PS4 threshold is OR > 5.0 with a confidence interval excluding 1.0, but no variant-specific OR, confidence interval, or comparable count data are available.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:21057493 reports TET2 functional and patient-level gene observations but does not mention c.5192del or p.(Gly1731AlafsTer14), and supplies no variant-specific case-control comparison.
  • No paper in literature_pass.json packet.ai_classified_papers was available for PS4 verification; no affected-case/control counts, OR, or 95% CI were present in the supplied evidence.
Still missing
  • A variant-specific case-control study or affected-case and matched-ancestry control counts are needed to calculate OR and its 95% CI.
Sources
PM3 ACMG_2015Not assessed: no documented pathogenic allele in trans or parent/offspring testing establishes phase for this variant. Details ▾Hide ▴
Reasoning

PM3 cannot be assessed because the available evidence does not document an affected proband with this variant, a pathogenic variant on the other allele, or parental/offspring testing establishing that the variants are in trans. The variant's frameshift consequence and absence from population databases do not establish allelic phase or satisfy PM3.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • The available case evidence identifies NM_001127208.3:c.5192del as a TET2 frameshift but provides no affected-proband allelic observation, second pathogenic allele, or parent/offspring phase result.
  • PM3 requires evidence that the variant is detected in trans with a pathogenic variant and requires parent or offspring testing to determine phase.
Still missing
  • Affected-proband observation with this variant is not documented.
  • A pathogenic variant on the other allele is not documented.
  • Parental or offspring testing establishing trans phase is not documented.
PM6 ACMG_2015Not assessed: no documented assumed de novo occurrence or parental testing is available for the proband. Details ▾Hide ▴
Reasoning

PM6 cannot be assessed because no evidence documents an assumed de novo occurrence in the proband. Neither parental testing nor a clinical report establishing de novo status without maternity and paternity confirmation is available.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • No case evidence documents an assumed de novo occurrence, parental testing, or a proband-level clinical observation supporting PM6.
Still missing
  • Evidence that the variant is de novo or assumed de novo
  • Parental variant testing or clinical documentation supporting de novo status
  • Documented proband phenotype and diagnosis
PP1 ACMG_2015Not assessed: no affected relatives, familial testing results, cosegregation observations, or informative meioses are documented. Details ▾Hide ▴
Reasoning

PP1 cannot be assessed because no affected family members, familial variant testing, cosegregation observations, or number of informative meioses are documented. The evidence also does not establish the relevant familial disease phenotype.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... Note: May be used as stronger evidence with increasing segregation data.
Evidence considered
  • No case evidence documents affected relatives, familial variant testing, cosegregation, informative meioses, or a disease phenotype suitable for segregation analysis.
Still missing
  • Affected family-member phenotypes and diagnoses
  • Variant testing results in affected and unaffected relatives
  • Number of informative meioses
  • Pedigree and segregation data
PP4 ACMG_2015Not assessed: the patient's phenotype and family history were not provided, so phenotype specificity for a single-gene disease cannot be evaluated. Details ▾Hide ▴
Reasoning

The supplied evidence does not provide the patient's phenotype or family history. Although TET2 germline disease literature is referenced at the gene level, no case-specific phenotype is available to determine whether it is highly specific for a disease with a single genetic etiology.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • Patient phenotype and family-history details are required to assess specificity for a single genetic etiology.
BS2 ACMG_2015Not assessed: no healthy-adult carrier or homozygote observation is reported, and early-age full penetrance is not established for this disorder. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available population records. gnomAD v2.1 and v4.1 report the variant absent, but absence does not establish that the variant was observed in a healthy adult. The case does not provide a healthy-adult carrier or homozygote observation, disease inheritance details, or evidence that full penetrance is expected at an early age, which are necessary to apply the criterion. The indel calling caveat further discourages treating absence from sequencing databases as evidence about healthy homozygotes.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1 and v4.1 report the variant absent, but provide no healthy-individual genotype observation.
  • No case evidence documents a healthy adult with the variant in the zygosity relevant to a recessive, dominant, or X-linked disorder.
  • No case evidence establishes full penetrance at an early age for the relevant disorder.
Still missing
  • A documented healthy adult carrying the variant in the relevant zygosity is required.
  • The disorder's inheritance pattern and expectation of full early-age penetrance are not established in the available evidence.
Sources
BS3 ACMG_2015Not assessed: no direct functional study shows that c.5192del has no damaging effect on TET2 function or splicing. Details ▾Hide ▴
Reasoning

No well-established functional study directly tested NM_001127208.3:c.5192del or p.(Gly1731AlafsTer14) and demonstrated no damaging effect on TET2 protein function or splicing. PMID:21057493 tested different TET2 mutants and reported reduced 5-hydroxymethylcytosine for most tested mutants, not a benign result for this variant.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:21057493, Results: the functional experiments evaluated other TET2 substitutions and found reduced 5-hydroxymethylcytosine for seven of nine tested mutant proteins; they did not test c.5192del or establish a normal-function result for it.
  • PMID:21057493, the paper-extracted search found no mention of TET2 c.5192del or p.(Gly1731Afs*14), so the study cannot establish BS3 for this variant.
Still missing
  • A validated, reproducible benign functional or splicing assay directly testing TET2 c.5192del/p.(Gly1731AlafsTer14) is unavailable.
  • Variant-specific normal-function assay controls and quantitative results are unavailable.
Sources
BS4 ACMG_2015Not assessed: no affected relatives with negative variant testing or pedigree evidence demonstrates lack of segregation. Details ▾Hide ▴
Reasoning

BS4 cannot be assessed because no affected family members with negative variant testing are documented. There is no pedigree, familial phenotype information, or segregation testing from which lack of segregation can be established, and no information is available to evaluate phenocopy or multiple-variant explanations.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • No case evidence documents affected relatives who lack the variant, a pedigree demonstrating non-segregation, or information addressing phenocopies or multiple pathogenic variants.
Still missing
  • Pedigree with affected relatives
  • Variant testing results in affected relatives
  • Familial phenotype characterization
  • Assessment for phenocopies or multiple pathogenic variants
BP2 ACMG_2015Not assessed: no phase-resolved observation shows a pathogenic variant in cis or, for a fully penetrant dominant disorder, in trans. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed because the available evidence does not document a pathogenic variant in cis with this variant or, for a fully penetrant dominant gene/disorder, a pathogenic variant in trans with this variant. No phase-resolved affected-proband or family observation is provided.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The available case evidence provides no phase-resolved observation involving this variant and another pathogenic variant.
  • BP2 requires observation in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observation in cis with a pathogenic variant in any inheritance pattern.
Still missing
  • A pathogenic variant in cis with this variant is not documented.
  • A pathogenic variant in trans in a fully penetrant dominant disorder is not documented.
  • Phase-resolved family or affected-proband data are not documented.
Not applicable · 10· recorded as not applicable Show reasons ▾Hide reasons ▴
PS1 N/ANot applicable: PS1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PS1 (Richards et al. 2015, PMID:25741868) requires the same amino acid change as a previously established pathogenic variant, evaluated regardless of the underlying nucleotide change. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, no altered amino acid exists at this position to compare against any previously established pathogenic missense variant, so PS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PS1 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM1 N/ANot applicable: PM1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM1 (Richards et al. 2015, PMID:25741868) applies to a missense variant located in a mutational hot spot and/or a critical, well-established functional domain without benign variation. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, no altered residue exists to evaluate for mutational hot-spot or critical-domain membership, so PM1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM1 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM5 N/ANot applicable: PM5 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM5 (Richards et al. 2015, PMID:25741868) requires a novel missense change at an amino acid residue where a different missense change has previously been determined to be pathogenic. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, no missense change exists at this residue to compare against a different pathogenic missense change at the same position, so PM5's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM5 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP2 N/ANot applicable: PP2 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PP2 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene with a low rate of benign missense variation, where missense variants are a common mechanism of disease. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, the gene's missense-constraint properties are irrelevant because no missense change is present to evaluate, so PP2's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PP2 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP3 N/ANot applicable: c.5192del is a frameshift predicted to cause p.(Gly1731AlafsTer14), outside PP3's missense or splice-region/intronic scope. Details ▾Hide ▴
Reasoning

PP3 is not applicable because NM_001127208.3:c.5192del is a frameshift variant, predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14), and the governing generic rule limits PP3 to missense or splice-region/intronic variants rather than truncating or protein-length-changing variants. The available SpliceAI max delta score of 0.011 is therefore not evaluated for PP3 and cannot be used to override the scope exclusion.

Rule
PP3/BP4 apply only to a missense variant, or to a splice-region/intronic variant via the SpliceAI path - never to a frameshift, nonsense, or other truncating/protein-length-changing variant.
Evidence considered
  • Variant consequence: frameshift, NM_001127208.3:c.5192del, predicted protein NP_001120680.1:p.(Gly1731AlafsTer14).
  • SpliceAI max delta score = 0.011 was not used because the variant is a truncating frameshift outside PP3 scope.
BP1 N/ANot applicable: BP1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP1 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene for which primarily truncating variants are known to cause disease. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, the gene's truncating-variant mechanism is irrelevant because no missense change is present to evaluate, so BP1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP1 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP4 N/ANot applicable: the frameshift predicts p.(Gly1731AlafsTer14), so SpliceAI max delta 0.011 cannot establish no gene-product impact under BP4. Details ▾Hide ▴
Reasoning

BP4 is not applicable because NM_001127208.3:c.5192del is a frameshift variant, predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). Under the governing rule, BP4 does not apply to frameshift or nonsense variants: a low SpliceAI score cannot establish no impact on the gene product when the truncating protein effect remains. The available SpliceAI max delta score of 0.011 is therefore not evidence for BP4.

Rule
BP4 on a frameshift or nonsense variant is not_applicable: a 'no predicted splice impact' result leaves the truncating protein effect in place, so it is not evidence of no impact on the gene product - a splice prediction for such a variant matters only to PVS1 (e.g. predicted rescue).
Evidence considered
  • Variant consequence: frameshift, NM_001127208.3:c.5192del, predicted protein NP_001120680.1:p.(Gly1731AlafsTer14).
  • SpliceAI max delta score = 0.011 was not used for BP4 because a no-splice-impact prediction does not negate the truncating protein effect.
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
TET2
Transcript
NM_001127208.3
Coding (HGVS c.)
NM_001127208.3:c.5192del
Protein (HGVS p.)
NP_001120680.1:p.(Gly1731AlafsTer14)
GRCh38
chr4:105275700 TG>T
GRCh37
chr4:106196857 TG>T
Location and type
Exon 11 · frameshift
COSMIC
COSV54406307

Gene diagram

Every interpreted variant in TET2, mapped onto the exon structure of NM_001127208.3. Select a row to find it on the plot.

TET2NM_001127208.3
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +498 bp
0.000
SpliceAI acceptor gainat +111 bp
0.000
SpliceAI donor lossat +416 bp
0.000
SpliceAI donor gainat -374 bp
0.011
Pangolin splice lossmagnitude shown
-0.050
Pangolin splice gain
0.035

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 N/ANot applicable: c.5192del is a frameshift predicted to cause p.(Gly1731AlafsTer14), outside PP3's missense or splice-region/intronic scope. Details ▾Hide ▴
Reasoning

PP3 is not applicable because NM_001127208.3:c.5192del is a frameshift variant, predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14), and the governing generic rule limits PP3 to missense or splice-region/intronic variants rather than truncating or protein-length-changing variants. The available SpliceAI max delta score of 0.011 is therefore not evaluated for PP3 and cannot be used to override the scope exclusion.

Rule
PP3/BP4 apply only to a missense variant, or to a splice-region/intronic variant via the SpliceAI path - never to a frameshift, nonsense, or other truncating/protein-length-changing variant.
Evidence considered
  • Variant consequence: frameshift, NM_001127208.3:c.5192del, predicted protein NP_001120680.1:p.(Gly1731AlafsTer14).
  • SpliceAI max delta score = 0.011 was not used because the variant is a truncating frameshift outside PP3 scope.
BP4 N/ANot applicable: the frameshift predicts p.(Gly1731AlafsTer14), so SpliceAI max delta 0.011 cannot establish no gene-product impact under BP4. Details ▾Hide ▴
Reasoning

BP4 is not applicable because NM_001127208.3:c.5192del is a frameshift variant, predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). Under the governing rule, BP4 does not apply to frameshift or nonsense variants: a low SpliceAI score cannot establish no impact on the gene product when the truncating protein effect remains. The available SpliceAI max delta score of 0.011 is therefore not evidence for BP4.

Rule
BP4 on a frameshift or nonsense variant is not_applicable: a 'no predicted splice impact' result leaves the truncating protein effect in place, so it is not evidence of no impact on the gene product - a splice prediction for such a variant matters only to PVS1 (e.g. predicted rescue).
Evidence considered
  • Variant consequence: frameshift, NM_001127208.3:c.5192del, predicted protein NP_001120680.1:p.(Gly1731AlafsTer14).
  • SpliceAI max delta score = 0.011 was not used for BP4 because a no-splice-impact prediction does not negate the truncating protein effect.
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001127208.3:c.5192del in TET2 is a frameshift variant predicted to produce NP_001120680.1:p.(Gly1731AlafsTer14). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for TET2, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).

2 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    This paper does not explicitly mention TET2 c.5192del or NP_001120680.1:p.(G1731Afs*14). It reports that TET2 catalytic impairment is associated with reduced genomic 5-hydroxymethylcytosine: several tested TET2 mutant proteins produced significantly less 5-hydroxymethylcytosine than wild-type TET2 in HEK293T-cell assays, and TET2 mutations in patients with myeloid malignancies were associated with low genomic 5-hydroxymethylcytosine. It therefore provides gene-level functional context but no variant-specific PS3 or BS3 evidence for c.5192del.
    Does not name this variant
    PMID 21057493 ↗
    Quoted passage
    DNA from cells expressing 7 of the 9 mutant Tet2 proteins tested -- H1802Q/R, R1817S/M, W1211R, P1287S and C1834D -- contained significantly less 5-hmC than DNA from cells expressing wild type Tet2 (Fig. 1e, Suppl. Figs. 3e, 6), confirming our previous conclusion that these mutations impair enzymatic activity.

    Results, paragraph describing quantitative 5-hmC assays in Tet2-expressing HEK293T cells; patient 5-hmC analysis in the subsequent paragraph

  • Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.
    No paper-specific finding is recorded.
    PMID 24315485 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV54406307, n = 1 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.